Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes

Oncology Letters

Volumn 1, Issue 2, 2010, Pages 247-252

  Kokufu, Ikuo ^a   Kohno, Norio ^b,c   Yamamoto, Masayuki ^a   Takao, Shintaro ^c  

^a Itami City Hospital   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

Adjuvant therapy; Bisphosphonate; Bone metastases; Breast cancer; Pamidronate

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PAMIDRONIC ACID; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT DECISION MAKING; SURVIVAL RATE;

EID: 77955738405     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000044     Document Type: Article

References (22)

1. Rodan GA and Fleisch HA: Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692-2696, 1996.
2. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J and Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785-1791, 1996.
3. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487, 1995.
4. Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, zoledronic acid induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001.
5. Crohns CA, Untch M and Konecny G: Different bisphosphonates have direct cytotoxic effects on three breast cancer cell lines and fresh breast cancer tumor tissue. Proc Am Soc Clin Oncol 20: abs. 2005, 2001.
6. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S and Tonini G: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14: 1468-1476, 2003.
7. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P and Sorsa T: MMP inhibition and down-regulation by bisphosphonates. Ann NY Acad Sci 878: 453-465, 1999.
8. Paterson AH: The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer 88: 3038-3046, 2000.
9. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR and Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55: 3551-3557, 1995.
10. Van der Pluijm G, Vloedgraven H, Van Beek E, Van der Wee-Pals L, Lowik C and Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698-705, 1996.
11. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998.
12. Diel IJ, Solomayer EF, Gollan C, Schutz F and Bastert G: Bisphosphonates in the reduction of metastases in breast cancer - results of the extended follow-up of the first study population. Proc Am Soc Clin Oncol 19: abs. 314, 2000.
13. Jaschke A, Bastert G, Solomayer EF, Costa S, Schuetz F and Diel IJ: Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up. J Clin Oncol 22: abs. 529, 2004.
14. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J and Pylkkanen L: Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219-3224, 2002.
15. Powles T, Paterson A, McCloskey E, Kurkilahti M and Kanis J: Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. J Clin Oncol 22: abs. 528, 2004.
16. Saarto T, Blomqvist C, Virkkunen P and Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19: 10-17, 2001.
17. Saarto T, Vehmanen L, Blomqvist C and Elomaa I: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. J Clin Oncol 22: abs. 527, 2004.
18. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M and Rudenstam CM: Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 18: 3925-3935, 2000.
19. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144, 2007.
20. Michiqami T, Wiliams P and Dallas M: Bisphosphonate may increase metastases to soft tissue sites in breast cancer and B-cell lymphoma. J Bone Miner Res 12 (Suppl. 1): s106, abs. 115, 1997.
21. Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM and Burckhardt P: Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 84: 788-792, 1992.
22. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, Jakesz R, Kubista E, Marth C, Greil R and on behalf of the ABCSG: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. J Clin Oncol 26: abs. LBA4, 2008.